Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04106115
Title DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE)
Acronym DURANCE
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University College, London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR


No variant requirements are available.